Table 3 Randomized Window-of-opportunity trials with molecularly targeted agents in patients with early-stage breast cancer
Author, Year [Reference] | Size | Study drug | Comparator | Duration of Treatment (days) | Findings |
|---|---|---|---|---|---|
Garwood (2010)78 | 29 | Fluvastatin 20 mg/day | Fluvastatin 80 mg/day | 21–42 | Fluvastatin reduced Ki-67 of high-grade tumors (p = 0.008); no difference between Fluvastatin 20 or 80 mg by Ki67 changes |
Martin (2010)79 | 23 | Celecoxib 400 mg/day | No treatment | 14 | −16.6% Ki-67 reduction under celecoxib (p = 0.056) |
DeCensi (2011)75 | 60 | Lapatinib 1500 mg/day | Placebo | 21 | 9% reduction in Ki-67 after lapatinib (p = 0.008) in HER2+ breast cancer |
Leary (2015)76 | 121 | Lapatinib 1500 mg/day | Placebo | 10–14 | ↓Ki-67 with Lapatinib (p < 0.001), both in HER2+ (p = 0.003) and HER2- (p = 0.017) |
Robertson (2020)77 | 48 | Capivasertib | Placebo | 4.5 | Capivasertib decreases Ki67 |
